Treace Medical reports preliminary Q4 2023 revenue ~$62M, full-year ~$187M above guidance

TREACE MEDICAL CONCEPTS, INC.

Preliminary Q4 revenue $61.8M–$62.2M, ~25% YoY increase; full-year revenue $186.7M–$187.1M, ~32% increase and above guidance of $182M–$186M.
Blended avg. revenue per Lapiplasty kit in Q4 was $6,437, a record high and 9% increase over Q4 2022.
Added ~164 new active surgeons in Q4 and ~468 for full year; total active surgeons ~2,855, up 20% YoY.
Direct sales reps at 227, up 35% over end of 2022; direct channel contributed 82% of Q4 revenue.
2024 financial guidance to be provided on the Feb 27, 2024 earnings call.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TREACE MEDICAL CONCEPTS, INC. reported the fourth quarter of 2023 results: revenue $61.8 million to $62.2 million.

Period: the fourth quarter of 2023
Revenue: $61.8 million to $62.2 million
Result: preliminary results

Exact text from the filing

Preliminary revenue of $61.8 million to $62.2 million in the fourth quarter of 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TREACE MEDICAL CONCEPTS, INC. reported the full-year 2023 results: revenue $186.7 million to $187.1 million.

Period: the full-year 2023
Revenue: $186.7 million to $187.1 million
Result: preliminary results

Exact text from the filing

Preliminary revenue of $186.7 million to $187.1 million for the full-year 2023

View on SEC.gov

Browse all earnings releases →

TREACE MEDICAL CONCEPTS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-002719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.